Literature DB >> 10217587

Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination.

S Spila-Alegiani1, S Salmaso, M C Rota, A E Tozzi, R Raschetti.   

Abstract

A 10-fold increase of reported adverse events following influenza vaccination in the 1995-1996 campaign was reported. To evaluate the relative reactogenicity of different influenza vaccines a prospective observational study was conducted in 72 Italian local health units (LHU) in the period October-December 1996. Of the 16,637 enrolled individuals aged 65 or more, 27.4% reported the occurrence of at least one adverse event within 72 h of vaccination. The odds ratios, adjusted through a multivariate logistic model, were highest for whole vaccine recipients. Most of the observed events were of moderate clinical severity and were mainly represented by local symptoms. None of the products was found to show an unusual or concerning reactogenicity profile, and no severe events associated with immunization were reported.

Mesh:

Substances:

Year:  1999        PMID: 10217587     DOI: 10.1016/s0264-410x(98)00467-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Adult preferences for influenza vaccines with lower likelihood of side effects.

Authors:  Paul V Effler; Stephania Tomlin; Sarah Joyce; Donna B Mak
Journal:  Hum Vaccin Immunother       Date:  2013-11-04       Impact factor: 3.452

2.  Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.

Authors:  Danuta M Skowronski; Barbara Strauss; Perry Kendall; Bernard Duval; Gaston De Serres
Journal:  CMAJ       Date:  2002-10-15       Impact factor: 8.262

3.  Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies.

Authors:  Yuichiro Ide; Yutaka Imamura; Satoko Ohfuji; Wakaba Fukushima; Saburo Ide; Chiyo Tsutsumi; Masahisa Koga; Kazuhiro Maeda; Yoshio Hirota
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.

Authors:  Itay Lotan; Mark A Hellmann; Yitzhak Friedman; Hadas Stiebel-Kalish; Israel Steiner; Adi Wilf-Yarkoni
Journal:  Neuromuscul Disord       Date:  2022-02-05       Impact factor: 4.296

5.  Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel.

Authors:  Itay Lotan; Adi Wilf-Yarkoni; Yitzhak Friedman; Hadas Stiebel-Kalish; Israel Steiner; Mark A Hellmann
Journal:  Eur J Neurol       Date:  2021-08-02       Impact factor: 6.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.